Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Other Accumulated Expenses (2016 - 2025)

CV Sciences (CVSI) has disclosed Other Accumulated Expenses for 10 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 23.96% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 23.96% year-over-year, with the annual reading at $1.1 million for FY2025, 23.96% down from the prior year.
  • Other Accumulated Expenses hit $1.1 million in Q4 2025 for CV Sciences, down from $1.5 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.6 million in Q2 2025 to a low of $1.1 million in Q4 2025.
  • Historically, Other Accumulated Expenses has averaged $1.4 million across 4 years, with a median of $1.5 million in 2024.
  • Biggest YoY gain for Other Accumulated Expenses was 6.85% in 2025; the steepest drop was 23.96% in 2025.
  • Year by year, Other Accumulated Expenses stood at $1.5 million in 2022, then dropped by 2.39% to $1.5 million in 2023, then dropped by 5.89% to $1.4 million in 2024, then fell by 23.96% to $1.1 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CVSI at $1.1 million in Q4 2025, $1.5 million in Q3 2025, and $1.6 million in Q2 2025.